2026-04-28T22:57:02Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/232012024-11-28T22:10:21Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Verd, Sergio
author
Verd, Mateo
2024-09-18T06:42:26Z
2024-09-18T06:42:26Z
2021-01-26
Verd S, Verd M. Commentary: Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness? [editorial]. Front Pharmacol. 2021 Jan 26;11:625295.
1663-9812
http://hdl.handle.net/20.500.13003/9109
https://hdl.handle.net/20.500.12105/23201
33574761
10.3389/fphar.2020.625295
Frontiers in Pharmacology
2-s2.0-85101030519
615977200001
L634131245
eng
Metabolic syndrome
Obesity
Down syndrome
Oxidative stress
Hyperthyroidism
Glutathione
Commentary: Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?
editorial